Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSLiraglutide is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) and a synthetic derivative of GLP-1 (7-37; Item No. 24887).1 It increases cAMP accumulation in BHK cells expressing GLP-1R (EC50 = 61 pM). Liraglutide (100-1,000 nM) inhibits cytokine- and free fatty acid-induced apoptosis of primary neonatal rat pancreatic β-cells by greater than 95 and 50%, respectively, effects that can be blocked by the GLP-1 receptor antagonist exendin-3 (9-39) or the PI3 kinase inhibitor wortmannin (Item No. 10010591).2 In a rat model of obesity induced by supplemental dietary candy, liraglutide (0.2 mg/kg, s.c., twice per day) decreases calorie intake, shifts food preference to a higher ratio of chow to candy, reverses weight and fat gains, and increases insulin sensitivity.3 Formulations containing liraglutide have been used as adjuncts in the treatment of type 2 diabetes and for chronic weight management in overweight or obese adults.
WARNING This product is not for human or veterinary use.
1. Potent derivatives of glucagon-
2. The long-
3. Liraglutide, a long-